Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis.
To estimate an efficacy of intravenous methylprednisolone pulse therapy (m-PSL) and the occurrence of corticosteroid-related side effects in children with autoimmune hepatitis (AIH), compared with oral corticosteroid therapy. The subjects consisted of nine children with AIH. Patients were divided into two groups. Group 1 was consisted of four patients who were treated with conventional oral prednisone therapy without m-PSL. Group 2 was consisted of five children who were treated with m-PSL as an induction therapy and maintained on oral prednisone. The median duration needed for normalization of alanine aminotransferase was 285 days (range 18-617 days) in group 1 and 54 days (range 15-116 days) in group 2. The most frequent side effects were obesity and growth retardation. The Z-score in group 1 tended to be lower than in group 2 and body mass index in group 1 tended to be higher than in group 2. The m-PSL may become a safe and effective therapy for children with AIH. Further study is needed to establish the appropriate therapy for AIH in children.